XBIT XBiotech Inc.
USHealthcareAs of 2026-10-07 10:15
Why XBIT matters now
XBiotech Inc. (XBIT) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.16 with +0.11% on the session and $65.9M in market capitalization; recent performance reads 1-month -2.53% and YTD -3.35%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.5M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -60.2%.
The latest indexable market news headline is "XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.52
P/S
0.00
EV/EBITDA
1.17
DCF Value
$4.08
FCF Yield
-60.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.1%
ROA
-28.7%
ROIC
-35.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.5M | $-0.18 |
| Q4 2025 | $0.00 | $-26.9M | $-0.88 |
| FY 2025 | $0.00 | $-45.5M | $-1.49 |
| Q3 2025 | $0.00 | $-6.0M | $-0.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.